Tuesday, August 29, 2006

Biotech News - New Study Aims to Uncover Genetic Factors for Hearing Loss

New Study Aims to Uncover Genetic Factors for Hearing Loss

International collaboration a first step in laying groundwork for
earlier diagnosis and treatment

08-29-2006

PHOENIX, AZ - AUGUST 29, 2006 - Researchers at the Translational
Genomics Research Institute (TGen), the House Ear Institute (HEI)
and other organizations have initiated a study to identify the genes
and genetic interactions involved in age-related hearing loss
(presbycusis). The study, which was funded primarily by The Seaver
Foundation, will use the latest state-of-the-art gene chip
technology to uncover the genetic predisposition of presbycusis, a
disorder thought to be caused by multiple genes, the environment and
ethnicity. Affymetrix, a company specializing in tools for
scientific research, is providing the micro-array technology
necessary for processing the DNA samples in this study. Through an
understanding of its molecular mechanisms, scientists hope to
develop earlier diagnostics and ultimately prevent the disorder.
Presbycusis is the loss of hearing that gradually occurs in most
individuals as they age. About 30-35 percent of adults between the
ages of 65 and 75 years have a hearing loss. It is estimated that 40-
50 percent of people 75 years and older have a hearing loss,
according to the National Institutes of Health, and it often leads
to isolation and depression.

"This study will serve as a foundation for gene discoveries in other
complex diseases and provides the groundwork for early diagnosis and
treatment of age-related hearing loss," said Rick A. Friedman, M.D.,
Ph.D., the principal investigator of the study at House Ear
Institute. Researchers at TGen, working with their counterparts at
the House Ear Institute, will utilize the Affymetrix technology to
examine DNA markers - 500,000 single-nucleotide polymorphisms (SNP) -
in high throughput fashion, which will provide them with the
opportunity to define the genetic basis of this prevalent disorder.
The study will evaluate nearly 2,000 patient samples collected at
the Hereditary Deafness Laboratory at the University of Antwerp,
Belgium. One of the short-term goals of the study is to create a
screening chip to identify variations in specific genes that lead to
presbycusis.

"This is a new era in medical research and our expertise in genetics
will allow inroads to be made into this disorder," said Dr. Dietrich
Stephan, head of TGen's Neurogenomics Division.

"Although it has been known that genes play an important role in age-
related hearing loss, the exact nature of these genes has not been
investigated until now," said Guy Van Camp, Ph.D., University of
Antwerp. "This project will put age-related hearing loss at the
forefront of genetic research."

# # #

About TGen
The Translational Genomics Research Institute (TGen), a non-profit
501(c)(3) organization, is focused on developing earlier diagnostics
and smarter treatments. Translational genomics research is a
relatively new field employing innovative advances arising from the
Human Genome Project and applying them to the development of
diagnostics, prognostics and therapies for cancer, neurological
disorders, diabetes and other complex diseases. TGen's research is
based on personalized medicine and the institute plans to accomplish
its goals through robust and disease-focused research.

About House Ear Institute
The House Ear Institute (HEI) is a non-profit 501(c)(3) organization
dedicated to advancing hearing science through research and
education to improve quality of life. Established in 1946 by Howard
P. House, M.D., as the Los Angeles Foundation of Otology, and later
renamed for its founder, the House Ear Institute has been engaged in
the scientific exploration of the auditory system from the ear canal
to the cortex of the brain for 60 years. HEI scientists continue to
explore the developing ear and ear diseases at the cell and
molecular level, as well as the complex ear-brain interaction. They
are also working to improve hearing aids and auditory implants,
diagnostics, clinical treatments and intervention methods. For
information on the House Ear Institute, please call (213) 483-4431
or visit the Web site at www.hei.org.

About the Hereditary Deafness Laboratory, University of Antwerp,
Belgium
This research group, headed by Dr. Guy Van Camp, has localized and
identified many genes for different forms of hereditary deafness
over the last 10 years. Most of this work was based on tissues from
large families, collected in Belgium and The Netherlands. Over the
last 2 years, this laboratory has started with the analysis of
complex forms of hearing impairment such as presbycusis and noise-
induced hearing impairment. These types of hearing impairment are
caused by a complex interplay between environmental factors, such as
noise or exposure to toxic substances or medication, and genes that
make people susceptible. The laboratory has developed new
methodologies for the analysis of these diseases.

About Affymetrix
Affymetrix is a pioneer in creating breakthrough tools that are
driving the genomic revolution. By applying the principles of
semiconductor technology to the life sciences, Affymetrix develops
and commercializes systems that enable scientists to improve quality
of life. The Company's customers include pharmaceutical,
biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit
research institutes. Affymetrix offers an expanding portfolio of
integrated products and services, including its integrated GeneChip
brand platform, to address growing markets focused on understanding
the relationship between genes and human health. Additional
information on Affymetrix can be found at www.affymetrix.com.

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Wednesday, August 16, 2006

Biotech News - NAU and TGen Awarded Grant to Develop High School Science Programs


Helping science teachers keep pace with biosciences

08-16-2006

Flagstaff and Phoenix, AZ, August 16, 2006-- Northern Arizona
University and the Translational Genomics Research Institute (TGen)
have been awarded a three-year grant from the Arizona Board of
Regents to give Arizona high school teachers the training they need
to best educate and advise students who have an interest in the
biosciences.
NAU and TGen will partner with Arizona high schools to help teachers
educate their students about career opportunities in science and the
skills required to excel in Arizona's biosciences industry.

The program, Biotechnology for Teachers: A Link Between Content and
Real-World Application, is an Improving Teacher Quality project that
will receive $122,000 for the first year and additional funding for
the following two years.

The grant supports collaboration among scientists and educators to
help secondary biology teachers update their biology content
knowledge and biotechnology laboratory skills.

"The goal is to increase teachers' content knowledge, awareness of
rapid advances in biotechnology, current and future uses of
biotechnology, hands-on laboratory skills and pedagogical knowledge
that can be transferred to students," said Catherine Ueckert, an
associate professor in biological sciences at NAU.

TGen, in collaboration with NAU's College of Engineering and Natural
Sciences and the Center for Science Teaching and Learning, will
implement the program through the Chino Valley School District, the
Tuba City School District and Mesa Public Schools.

NAU, TGen and the schools will collaboratively develop programs that
give high school teachers exposure and opportunities to learn about
science. For example, teachers will participate in professional
development opportunities in biotechnology, earn 24 NAU graduate
college credits free of charge, and explore ways to prepare their
students for the science component of the AIMS test.

A highlight of Biotechnology for Teachers is authentic laboratory
experiences facilitated by TGen on the genetic basis of various
diseases and disorders.

"TGen is proud of our partnership with NAU and is eager to share our
knowledge and expertise in genomics and bioscience with teachers
across the state," said Candice Nulsen, TGen education program
manager. "We look forward to helping science educators learn more
about how the biosciences may be applied to a real-world setting."
According to Nena Bloom from NAU's Center for Science Teaching and
Learning, NAU will oversee the coordination and teaching of the
program, including a variety of coursework such as methods of
biotechnology and genetics/molecular biology.

"The program will also provide professional development in a
collaborative setting with TGen to help teachers use biotechnology
laboratories efficiently and effectively in their classrooms," Bloom
said.

Teachers also will be educated about current topics on the ethical,
legal and social implications of genomics and participate in grant-
writing workshops.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit
501(c)(3) organization focused on developing earlier diagnostics and
smarter treatments. Translational genomics research is a relatively
new field employing innovative advances arising from the Human
Genome Project and applying them to the development of diagnostics,
prognostics and therapies for cancer, neurological disorders,
diabetes and other complex diseases. TGen's research is based on
personalized medicine. The institute plans to accomplish its goals
through robust and disease-focused research.

About Northern Arizona University (NAU)
NAU has earned a solid reputation as a comprehensive university with
a personal touch and an outstanding research component. The personal
attention comes in many forms, including small classes with full-
time professors who know their students' names and a caring and
committed staff whose goal is to help every student succeed. While
the university's emphasis is undergraduate education, it offers
graduate programs and research that builds from its base on the
Colorado Plateau and extends to such national concerns as forest
health and genetics. Internationally recognized environmental
research, including disease ecology, programs give student unique
training opportunities. www.nau.edu.

http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

NAU and TGen Awarded Grant to Develop High School Science Programs

NAU and TGen Awarded Grant to Develop High School Science Programs


Helping science teachers keep pace with biosciences

08-16-2006

Flagstaff and Phoenix, AZ, August 16, 2006-- Northern Arizona University and the Translational Genomics Research Institute (TGen) have been awarded a three-year grant from the Arizona Board of Regents to give Arizona high school teachers the training they need to best educate and advise students who have an interest in the biosciences.
NAU and TGen will partner with Arizona high schools to help teachers educate their students about career opportunities in science and the skills required to excel in Arizona's biosciences industry.

The program, Biotechnology for Teachers: A Link Between Content and Real-World Application, is an Improving Teacher Quality project that will receive $122,000 for the first year and additional funding for the following two years.

The grant supports collaboration among scientists and educators to help secondary biology teachers update their biology content knowledge and biotechnology laboratory skills.

"The goal is to increase teachers' content knowledge, awareness of rapid advances in biotechnology, current and future uses of biotechnology, hands-on laboratory skills and pedagogical knowledge that can be transferred to students," said Catherine Ueckert, an associate professor in biological sciences at NAU.

TGen, in collaboration with NAU's College of Engineering and Natural Sciences and the Center for Science Teaching and Learning, will implement the program through the Chino Valley School District, the Tuba City School District and Mesa Public Schools.

NAU, TGen and the schools will collaboratively develop programs that give high school teachers exposure and opportunities to learn about science. For example, teachers will participate in professional development opportunities in biotechnology, earn 24 NAU graduate college credits free of charge, and explore ways to prepare their students for the science component of the AIMS test.

A highlight of Biotechnology for Teachers is authentic laboratory experiences facilitated by TGen on the genetic basis of various diseases and disorders.

"TGen is proud of our partnership with NAU and is eager to share our knowledge and expertise in genomics and bioscience with teachers across the state," said Candice Nulsen, TGen education program manager. "We look forward to helping science educators learn more about how the biosciences may be applied to a real-world setting." According to Nena Bloom from NAU's Center for Science Teaching and Learning, NAU will oversee the coordination and teaching of the program, including a variety of coursework such as methods of biotechnology and genetics/molecular biology.

"The program will also provide professional development in a collaborative setting with TGen to help teachers use biotechnology laboratories efficiently and effectively in their classrooms," Bloom said.

Teachers also will be educated about current topics on the ethical, legal and social implications of genomics and participate in grant-writing workshops.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine. The institute plans to accomplish its goals through robust and disease-focused research.

About Northern Arizona University (NAU)
NAU has earned a solid reputation as a comprehensive university with a personal touch and an outstanding research component. The personal attention comes in many forms, including small classes with full-time professors who know their students' names and a caring and committed staff whose goal is to help every student succeed. While the university's emphasis is undergraduate education, it offers graduate programs and research that builds from its base on the Colorado Plateau and extends to such national concerns as forest health and genetics. Internationally recognized environmental research, including disease ecology, programs give student unique training opportunities. www.nau.edu.

Tuesday, August 15, 2006

Exelixis, Inc. EXEL - Exelixis Initiates Phase II Clinical Development Program for XL647 in Patients With Metastatic Non-Small Cell Lung Cancer

Exelixis, Inc. EXEL - Exelixis Initiates Phase II Clinical Development Program for XL647 in Patients With Metastatic Non-Small Cell Lung Cancer

- Study targets previously untreated patients -
Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of a Phase II trial of
XL647, an orally bioavailable small molecule inhibitor of the HER2, EGF,
VEGF and EphB4 receptor tyrosine kinases (RTKs). Although these individual
RTKs are targets for currently approved therapies, XL647 was designed to
potently inhibit all three targets simultaneously. The trial will be
conducted in patients with advanced (stage IIIB or IV) non-small cell lung
cancer (NSCLC) who have not previously been treated with chemotherapy. In
this proof-of-concept trial, participants must meet at least two of the
following criteria: asian, female, non-smoker or adenocarcinoma.
"We designed XL647 to potently inhibit EGFR and VEGFR, as well as HER2
and EphB4. We believe that simultaneously inhibiting this spectrum of
targets may provide greater efficacy than has been achieved to date by
inhibiting these targets individually," said George A. Scangos, Ph.D.,
president and chief executive officer of Exelixis. "As a single compound
optimized for potency, activity, safety and tolerability, we believe the
safety and tolerability profile of XL647 may be better than those from
combinations of drugs designed to inhibit individual targets."
The multi-center, open-label Phase II study will be conducted in up to
15 clinical sites and will follow a two-stage enrollment strategy. The
primary objectives of the Phase II study are to determine the response rate
of subjects with NSCLC treated with XL647 and to evaluate the safety and
tolerability of XL647. Secondary objectives include assessment of
progression-free survival, duration of response, and overall survival, and
characterization of pharmacokinetic and pharmacodynamic parameters of
XL647.
As reported in June 2006 at the American Society of Clinical Oncology
(ASCO) annual meeting, XL647 has exhibited favorable safety and
tolerability profiles in a Phase I trial in patients with advanced solid
tumors. The investigators reported that of 40 evaluable patients, one
patient (non-small cell lung cancer [NSCLC]) has had a partial response and
12 others (NSCLC [3], chordoma [2], adenoid cystic carcinoma [2],
adrenocortical carcinoma, colorectal, ovarian, mesothelioma and head and
neck cancer) have had prolonged stable disease (>3.5 months). The first two
patients treated at the 7.0 mg/kg dose experienced dose-limiting toxicities
(DLTs) of grade 3 diarrhea, which resolved upon a reduction in dose to 4.68
mg/kg. One serious adverse event of grade 4 pulmonary embolism was
considered potentially related to study treatment in a patient treated at
the 0.28 mg/kg dose. One patient at the 3.12 mg/kg dose had an asymptomatic
QTc prolongation on electrocardiogram. Expansion of the 4.68 mg/kg cohort
to six patients occurred without further DLTs, and this is considered the
maximum tolerated dose.
About XL647
XL647 is a potent inhibitor of multiple RTKs implicated in driving
tumor cell proliferation and tumor vascularization (blood vessel
formation). XL647 inhibits the EGF, HER2, and VEGF RTKs, each of which is a
target of currently approved cancer therapies. In addition, XL647 inhibits
EphB4, an RTK that is highly expressed in many human tumors and plays a
role in promoting angiogenesis. In a broad array of preclinical tumor
models including breast, lung, colon and prostate cancer, XL647
demonstrated potent inhibition of tumor growth and caused tumor regression.
In cell culture models, XL647 retained significant potency against mutant
EGFRs that cause resistance to current EGFR inhibitors.
About Exelixis
Exelixis, Inc. is a biotechnology company dedicated to the discovery
and development of novel therapeutics that will potentially enhance the
care and lives of patients with cancer and other serious diseases. The
company is leveraging its fully integrated gene-to-drug platform to fuel
the growth of its proprietary drug pipeline. Exelixis' development pipeline
covers cancer and metabolism and is comprised of the following compounds:
XL119 (becatecarin), for which a multinational Phase III clinical trial in
bile duct tumor is ongoing and which has been exclusively licensed to
Helsinn Healthcare S.A.; XL784, which is being advanced in a Phase II trial
as a treatment for renal disease; XL999, an anticancer compound currently
in Phase II clinical trials for a variety of solid tumors and hematologic
malignancies; XL647 an anticancer compound currently in Phase II clinical
trials for advanced non-small cell lung cancer; XL820, XL844 and XL184,
anticancer compounds currently in Phase I clinical trials; and multiple
compounds in preclinical development for diseases including cancer and
various metabolic and cardiovascular disorders. Exelixis has established
broad corporate alliances with major pharmaceutical and biotechnology
companies including GlaxoSmithKline (GSK) and Bristol-Myers Squibb Company.
Pursuant to a product development and commercialization agreement between
Exelixis and GSK, GSK has the option, after completion of clinical
proof-of-concept by Exelixis, to elect to develop a certain number of
compounds in Exelixis' product pipeline, which may include XL784 and the
cancer compounds identified in this press release (other than XL119), thus
potentially triggering milestone payments and royalties from GSK and
co-promotion rights by Exelixis. For more information, please visit the
company's web site at http://www.exelixis.com .
This press release contains forward-looking statements, including
without limitation statements related to Exelixis' clinical development
program for XL647 and the therapeutic potential of XL647. Words such as
"believes," "anticipates," "plans," "expects," "intends," "will," "slated,"
"goal" and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon Exelixis'
current expectations. Forward-looking statements involve risks and
uncertainties. Exelixis' actual results and the timing of events could
differ materially from those anticipated in such forward-looking statements
as a result of these risks and uncertainties, which include, without
limitation, the potential failure of product candidates to demonstrate
safety and efficacy in clinical testing; the ability of Helsinn Healthcare
S.A. to conduct the Phase III clinical trial of XL119 sufficient to achieve
FDA approval; the ability to complete and initiate trials at the referenced
times; the ability to conduct clinical trials sufficient to achieve a
positive completion; the ability to file INDs at the referenced times; the
ability of Exelixis to advance additional preclinical compounds into
clinical development; the uncertainty of the FDA approval process; and the
therapeutic and commercial value of the company's compounds. These and
other risk factors are discussed under "Risk Factors" and elsewhere in our
quarterly report on Form 10-Q for the quarter ended March 31, 2006 and
other filings with the Securities and Exchange Commission. The company
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in the company's expectations with regard thereto or any
change in events, conditions or circumstances on which any such statements
are based.


SOURCE Exelixis, Inc.



Biotech News

Celera Genomics, Applera Corp CRA - G/O Business Solutions, Inc. Announces Completion of the Reorganization Transaction

Celera Genomics, Applera Corp CRA - G/O Business Solutions, Inc. Announces Completion of the Reorganization Transaction Entered into with SH Celera Capital Corporation.

Aug. 15, 2006--Today, G/O Business Solutions, Inc., a Colorado corporation (OTCBB:GOBS), formerly G/O International, Inc. ("G/O"), and SH Celera Capital, a Maryland corporation ("SH Celera") (SH Celera, together with G/O, the "Parties") announced the completion of the Reorganization Transaction previously announced in July of 2006.


Pursuant to the terms of the Reorganization Plan and Agreement and ancillary documents executed and delivered in connection therewith:

SH Celera:

(i) assumed up to $65,000 of the current liabilities of G/O;

(ii) provided G/O with working capital of $50,000;

(iii) enter into a Facilities Administration and Operating Services Agreement as described herein below;

(iv) Pursuant to a Mutual Undertaking Agreement, executed and delivered at the time of Closing of the Reorganization Transaction, committed to issue 486,053 shares of its $0.001 par value per share common stock to G/O, for further distribution to the G/O stockholders, determined at the time of closing of the Reorganization Transaction, upon fulfillment of the following conditions: G/O shall have raised not less than $2,500,000 in the Contemplated Financing (as described herein below), (ii) SH Celera shall have: (a) registered its shares of common stock under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the "34 Act"), (b) taken such steps as required to qualify its shares of common stock as "Covered Securities" as defined in Section 18 of the Securities Act of 1933, as amended (the "33 Act"), and (c) register the shares of common stock issuable to G/O in the Reorganization Transaction for distribution to G/O's stockholders, determined at the time of the closing of the Reorganization Transaction, pursuant to the 33 Act.

(v) Pursuant to Assignment, Assumption and Confirmation Agreements, executed and delivered at the time of Closing, assigned to G/O all of its rights under certain Retainer Agreement(s), entered into by SH Celera, pursuant to which SH Celera has received the right to receive certain fees in connection with providing fee based business consulting services.

In consideration therefore, G/O:

(i) changed its name from G/O International, Inc., to G/O Business Solutions, Inc., through filing Amended and Restated Articles of Incorporation;

(ii) appointed George Jarkesy as a member of its board of directors to fill the vacancy created by the resignation of Michael Caswell and appointed Mr. Jarkesy to serve as G/O's Chairman and Chief Executive Officer. In connection with Mr. Jarkesy's appointment, G/O executed and delivered an Indemnification Agreement providing Mr. Jarkesy full protection under Colorado law.

(iii) reverse split its outstanding shares of $0.01 par value per share common stock in the ratio of 1 for 2, effective August 15, 2006;

(iv) obtained a new Cusip Number which is 362985 10.3 and a new trading symbol which is "GOBS";

(v) delivered to SH Celera a total of 17,300,744 (post 1 for 2 reverse split) newly issued shares of its $0.01 par value per share restricted common stock;

(vi) transferred to SH Celera a total of 356,999 shares of Waterbury Resources, Ltd., a Cayman Islands company;

(vii) enter into the Facilities Administration and Operating Services Agreement, and the Assignment, Assumption and Confirmation Agreement respecting the assigned Retainer Agreements, as described herein below, and undertook providing fee based business consulting services pursuant thereto; and

(viii) pursuant to the Mutual Undertaking Agreement undertook to complete the Contemplated Financing as described herein below.

At the time of closing of such Reorganization Transaction:

A. SH Celera had issued and outstanding a total of 9,235,000 shares of its $0.001 par value per share common stock. Consequently, the 486,053 shares of SH Celera's common stock, issuable to G/O for distribution to its stockholders, will represent 5% of the issued and outstanding shares of SH Celera's common stock, as of the date of the closing of the Reorganization Transaction.

B. G/O, after giving effect to the 1 for 2 reverse split, has issued and outstanding a total of 4,325,186 shares of its $0.01 par value per share common stock. Consequently, G/O now has outstanding a total of 21,625,930 shares of its $0.01 par value per share common stock, of which 17,300,744 shares or 80% are owned by SH Celera and 4,325,186 shares or 20% are owned by the existing stockholders of G/O.

Facilities, Administration and Operating Services Agreement.

At the time of closing of the Reorganization Transaction, G/O and SH Celera enter into a Facilities Administration and Operating Services Agreement (the "FA&OS Agreement"), pursuant to which SH Celera has agreed to provide all facilities, administration and operating services necessary for G/O to conduct a fee based business consulting practice under the trade name of "G/O Business Solutions, Inc." The FA&OS Agreement provides that SH Celera will be paid a monthly fixed fee of $10,000 per month ("Fixed Fee") and will be reimbursed one half of the monthly salary of Brian Rodriguez (or $4,166 per month) and all of the monthly salary of Dwayne Deslatte (or $6,250 per month) (the "SH Celera Staff Reimbursement") with the balance of cash income generated from such cash fees, after payment of the Fixed Fee and the SH Celera Staff Reimbursement, split equally between G/O and SH Celera. The FA&OS Agreement also provides that any non-cash fees received by G/O, in connection with providing the consulting services, will be distributed directly to G/O's stockholders and, in the case of share compensation received from a client company, shall be distributed by G/O pursuant to a registration of such shares under the 33 Act. Such FA&OS Agreement will remain in effect until the earlier of: G/O successfully raising not less than $2,500,000 in the Contemplated Financing, as set forth herein below, or G/O having accumulated cash reserves equaling not less than one year's projected required operating cash.

G/O's Contemplated Financing.

Pursuant to a Mutual Undertaking Agreement executed and delivered by G/O and SH Celera in connection with the Reorganization Transaction, G/O has agreed to undertake to raise, in a private placement, a minimum of $2,500,000 and up to $5,000,000 in equity capital through the sale of its shares of preferred stock with the following rights, duties and preferences (the "Contemplated Financing"): (i) a stated value equal to the price per share paid for the shares of preferred stock plus accumulated and unpaid dividends, (ii) a dividend preference equal to a fixed annual percentage rate (to be determined by G/O's Board of Directors) multiplied times the stated value of each share of preferred stock, which shall be cumulative and paid before any dividends respecting any other class of shares ("Fixed Rate Dividend") plus a fixed percentage participation in distributions to stockholders, (to be determined by G/O's Board of Directors), which shall be paid at the time of any distribution to any of G/O's stockholders, (iii) a liquidation preference equal to the stated value plus any accumulated and unpaid Fixed Rate Dividends, (iv) a securitization of the stated value and a portion of the Fixed Rate Dividend through the purchase and deposit by G/O of a fixed rate financial instrument suitable to the purchaser(s) of the preferred stock, and (v) representation on G/O's Board of Directors or the right to attend and observe board meetings, at the discretion of the majority of the holders of the preferred stock.

G/O's Board of Directors will, subject to the approval of SH Celera, determine the terms upon which such shares of Preferred Stock are sold and the rights and privileges granted to purchasers of the shares of Preferred Stock, including, but not limited to: (i) the price per share, (ii) the granting of conversion features, (iii) the fixed dividend rate, (iv) the nature of the securitization including the coverage ratio on the Stated Value and the differential on the dividend rate and (v) the percentage participation in future dividends and distributions to G/O's stockholders.

As a result of the Reorganization Transaction, G/O now offers consulting services in the areas of:

-- Corporate Development;

-- Merger and Acquisition Planning;

-- Market Divestiture and Special Situations;

-- Growth Strategies and Logistics - Review, Development and Implementation Procedures;

-- Succession Planning;


Biotech News

Diversa Corporation DVSA - Diversa Corporation lowered its outlook for fiscal 2006.

Diversa Corporation DVSA - Diversa Corporation lowered its outlook for fiscal 2006.

The Company expects 2006 total revenue to be between $48 and $52 million, with product-related revenue of $15 to $18 million. The Company expects its net loss for the full year to be between $39 and $42 million as compared to $89.7 million in 2005. The expected net loss for 2006 includes $10.8 million in restructuring charges and $5.4 million in non-cash share-based compensation expense. According to Reuters Estimates, analysts on average are expecting the Company to report net loss of $25.20 million on revenues of $51.25 million in the same period.


Biotech News

Lexicon Genetics Incorporated LEXG - Lexicon Genetics to Report Second Quarter 2006 Financial Results

Lexicon Genetics Incorporated LEXG - Lexicon Genetics to Report Second Quarter 2006 Financial Results on August 1, 2006
Tuesday July 18, 4:30 pm ET
Conference Call and Webcast to Follow


Lexicon Genetics Incorporated (Nasdaq: LEXG - News) will release its second quarter 2006 financial results on Tuesday, August 1, 2006 before the financial markets open. Lexicon management will hold a conference call to discuss the company's results and provide financial guidance for the third quarter at 11:00 a.m. Eastern Time on August 1, 2006.

The dial-in number for the conference call is 800-946-0782 (within the United States) or 719-457-2657 (international). The pass code for all callers is 5952224. Investors can access http://www.lexicon-genetics.com to listen to a live webcast of the call. The webcast will be archived and available for review through August 4, 2006.

About Lexicon Genetics

Lexicon Genetics is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs addressing these targets. For targets that the company believes have high pharmaceutical value, it engages in programs for the discovery and development of small molecule, antibody and protein drugs. Lexicon has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through collaborations and strategic alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com .

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.




Source: Lexicon Genetics Incorporated


Biotech News

Nuvelo, Inc. NUVO - Archemix and Nuvelo Expand Collaboration and Nominate New Clinical Compound

Nuvelo, Inc. NUVO - Archemix and Nuvelo Expand Collaboration and Nominate New Clinical Compound

Archemix Corp. and Nuvelo, Inc. (Nasdaq: NUVO - News) today announced that they have expanded their collaboration agreement. Under the new agreement, which replaces the existing 50/50 collaboration, Archemix will be responsible for the discovery of short-acting aptamers targeting the coagulation cascade for use in acute cardiovascular procedures, and Nuvelo will be responsible for the development and worldwide commercialization of these aptamers. In addition, Nuvelo has designated NU172 (ARC2172), a short-acting, direct thrombin inhibiting aptamer, as a development candidate.

Under the new collaboration agreement, Nuvelo will make an initial upfront payment to Archemix of $4.0 million and, under certain circumstances may invest up to $10.0 million in Archemix's common stock upon an initial public offering. Nuvelo will also fund Archemix research in the area of short-acting aptamers for the next three years at a minimum of $5.25 million. In addition, Archemix may receive payments totaling up to $35.0 million per development compound on the achievement of specified development and regulatory milestones, along with potential royalty payments based on sales of licensed compounds. At the initiation of the first Phase 3 study for any licensed compound, Archemix has the option to elect to participate in profits from sales of the compound by funding its pro rata share of prior and future product development and commercialization expenses, in lieu of receiving milestone payments and royalties with respect to that compound.

"The development of anticoagulants with rapid onset and offset of action continues to represent a great opportunity as there is an unmet medical need for an anticoagulant with fewer side effects and more predictable dosing than heparin combined with its antidote, protamine," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "This strategic alliance with Archemix maximizes our respective core competencies -- Archemix's unparalleled expertise in the identification and optimization of aptamers and Nuvelo's cardiovascular development capability. It will also allow both companies to benefit from the acute cardiovascular commercial infrastructure that we are putting in place to support the launch of our lead compound, alfimeprase."

"The expansion of our existing collaboration highlights the potential of aptamers as a novel source of therapeutics," said Dr. Errol De Souza, president and chief executive officer of Archemix. "Although the original molecule developed under the prior agreement, ARC183, demonstrated proof-of-concept in the clinic, it was not optimal for further clinical development due to its lower potency. The rapid discovery cycle times associated with aptamers allowed us to generate a more potent development candidate, NU172, within one year of initiation of the project. Recognizing the potential of NU172 and the need for short-acting anticoagulants in general, Nuvelo elected to expand our collaboration and build upon the foundation of clinical learning we achieved during the term of our original agreement. We are very enthusiastic about expanding our collaboration with Nuvelo and leveraging each others' strengths to the mutual benefit of the collaboration."

NU172 is an aptamer that directly inhibits thrombin's ability to generate fibrin, the protein that provides the scaffolding for blood clots. Data from early animal models suggest that NU172 is a potent anticoagulant that offers the potential for predictable anticoagulant effects, rapid onset and offset of action, reduced bleeding complications and no risk of heparin induced thrombocytopenia. Nuvelo has already commenced IND-enabling studies with NU172.

About Aptamers

Aptamers are single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical stability, low toxicity and immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed, offering a significant cost advantage.

About Archemix

Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge, Massachusetts. The company's mission is to develop aptamers as a class of directed therapeutics for the prevention and treatment of human disease. Because of their unique properties and proven efficacy, aptamers offer an alternative to biologics and small molecules in numerous applications and offer the potential to be a major class of drugs for the treatment of unmet medical needs.

Archemix's aptamer expertise is complemented by a robust patent estate comprised of over 220 issued and 230 pending patents covering the identification, composition, and use of therapeutic aptamers. In addition to the company's core aptamer generation technology, Archemix possesses strong expertise in both preclinical and clinical drug development. Further information on Archemix can be found at www.archemix.com or call 212-588-8788.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in four Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex which recently completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, which includes NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.

Nuvelo Safe Harbor

This press release contains "forward-looking statements" regarding the timing and progress of Nuvelo's clinical programs, the potential improvement or benefit that current and future clinical trial programs may demonstrate, the numbers of patients who may be eligible for treatment, and the anticipated commercial launch of alfimeprase, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's annual report on Form 10-K for the year ended December 31, 2005 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.




Source: Nuvelo, Inc.


Biotech News

Incyte Corporation INCY - Incyte Announces Second Quarter Financial Results

Incyte Corporation INCY - Incyte Announces Second Quarter Financial Results; Provides Update on Drug Discovery and Development Programs; Conference Call

July 27, 2006--Incyte Corporation (Nasdaq:INCY) today announced its financial results for the second quarter 2006 and reported on the Company's most advanced drug discovery and development programs.


Recent developments include:

-- Initiation of Phase I testing in healthy volunteers of an internally developed oral CCR5 antagonist, INCB9471, for treatment of HIV.

-- Initiation of Phase I testing in healthy volunteers of an internally developed oral inhibitor of 11-beta hydroxysteroid dehydrogenase type 1, INCB13739, a potential new medicine for Type 2 diabetes.

-- Continued progress with several internally developed compounds that are expected to advance into clinical development including INCB8696, an oral CCR2 antagonist for multiple sclerosis, and two additional compounds, one in inflammation and a second in oncology.

-- Election of two new members to Incyte's Board of Directors: John Niblack, Ph.D., former Pfizer Inc Vice Chairman and President of Global Research and Development, and Matthew Emmens, Chief Executive Officer of Shire plc, a global specialty pharmaceuticals company.

Paul Friedman, MD, Incyte's President and Chief Executive Officer stated, "If our programs progress as we expect they will over the next twelve months, Incyte could have up to six compounds in Phase II clinical development and multiple opportunities to demonstrate the potential value of our drug discovery and development efforts."

Financial Results

Cash Position

As of June 30, 2006, cash, short-term and long-term marketable securities totaled $352.7 million, compared to $345.0 million as of December 31, 2005.

During the six months ended June 30, 2006, the Company used $44.6 million in cash and marketable securities, excluding the following:

-- $40 million upfront payment received from Incyte's collaborative research and license agreement with Pfizer;

-- $10 million received through the purchase of a Convertible Subordinated Note by Pfizer in connection with Incyte's collaborative research and license agreement; and

-- $2.3 million resulting from the increased market value of a strategic investment included in marketable securities.

The Company expects to use between $88 and $95 million in cash in 2006. This cash use range is unchanged from previous guidance and excludes any possible in-licenses or purchases of products, the repurchase of any of its 5.5% Convertible Subordinated Notes, any activity related to its strategic investments and any funds received from its collaboration with Pfizer.

Revenues

Revenues for the quarter ended June 30, 2006 were $6.9 million, as compared to $2.7 million for the same period in 2005. Revenues for the six months ended June 30, 2006 were $13.3 million, as compared to $5.6 million for the same period in 2005. The increase was the result of revenues recognized under Incyte's collaborative research and license agreement with Pfizer.

Net Loss

The net loss for the quarter ended June 30, 2006 was $20.5 million, or $0.24 per share, as compared to $25.1 million, or $0.30 per share, for the same period in 2005. Included in the net loss for the quarter ended June 30, 2006 was the following:

-- $1.3 million charge recorded in interest and other income, net as a result of a write-down related to the reduced market valuation of a strategic investment that Incyte holds in another company;

-- $3.4 million charge recorded in other operating expenses related to the settlement of litigation with Invitrogen Corporation related to Incyte's discontinued genomic information business. This settlement resolves all outstanding claims included in the litigation; and

-- $2.3 million of non-cash expense related to the impact of expensing share-based payments, including employee stock options.

Included in the net loss for the quarter ended June 30, 2005 was a $2.8 million gain from the sale of a strategic investment recorded in interest and other income, net.

The net loss for the six months ended June 30, 2006 was $37.8 million or $0.45 per share, as compared to $45.3 million or $0.54 per share, for the same period in 2005. Included in the net loss for the six months ended June 30, 2006 was the following:

-- $5.5 million gain from the sale of a portion of a strategic investment, recorded in the first quarter of 2006 in interest and other income, net; and

-- $4.6 million of non-cash expense for the six months ended June 30, 2006, related to the impact of expensing share-based payments, including employee stock options.

Operating Expenses

Research and development expenses for the quarter ended June 30, 2006 were $19.7 million, as compared to $26.6 million for the same period last year. Included in research and development expenses for the quarter ended June 30, 2006 was a non-cash expense of $1.4 million related to the impact of expensing share-based payments, including employee stock options. The decrease in research and development expenses results from the Company's collaborative research and license agreement with Pfizer and the decision in April 2006 to terminate the development of its DFC program. Research and development expenses for the six months ended June 30, 2006 were $44.5 million, as compared to $44.3 million for the same period last year. Included in research and development expenses for the six months ended June 30, 2006 was a non-cash expense of $2.9 million related to the impact of expensing share-based payments, including employee stock options. The Company expects its research and development expenses to vary from quarter to quarter, primarily due to the timing of its clinical development activities.

Selling, general and administrative expenses for the quarter ended June 30, 2006 were $3.4 million, as compared to $2.7 million for the same period last year. Included in selling, general and administrative expenses for the quarter ended June 30, 2006 was a non-cash expense of $0.9 million related to the impact of expensing share-based payments, including employee stock options. Selling, general and administrative expenses for the six months ended June 30, 2006 were $7.3 million, as compared to $5.5 million for the same period last year. Included in selling, general and administrative expenses for the six months ended June 30, 2006 was a non-cash expense of $1.7 million related to the impact of expensing share-based payments, including employee stock options.

Interest Income (Expense)

Interest income for the three and six months ended June 30, 2006 was $4.0 million and $7.3 million, respectively, as compared to $2.6 million and $4.8 million for the comparable periods last year. Interest expense for the three and six months ended June 30, 2006 was $3.9 million and $7.8 million, respectively, as compared to $4.1 million and $8.4 million for the comparable periods last year. Due to higher average cash balances and higher yields on its investment portfolio, the Company is increasing its 2006 interest income guidance from $8.0 to $9.0 million to $11.0 to $12.0 million.

Update on Drug Discovery and Development

Oncology Portfolio

Sheddase Inhibitor

Our lead clinical compound, INCB7839, is in a Phase Ib/IIa rising dose trial involving refractory cancer patients with solid tumors. The primary objectives for this trial are to establish the maximum tolerated dose and to select a dose for use in Phase II studies scheduled to start later this year and early next year. In the Phase II trials we expect to focus on specific solid tumor types such as breast, NSCLC, and/or colon cancer.

New Program

We have identified a lead development candidate for a second oncology program. Provided the compound successfully completes preclinical toxicology testing, we expect to file an Investigational New Drug Application (IND) for this compound by year-end.

Inflammation Portfolio

CCR2 Antagonist Program

Under our collaborative research and license agreement with Pfizer, we have retained exclusive worldwide rights to certain CCR2 antagonist compounds for multiple sclerosis (MS) and a second indication which, for competitive reasons, we have not disclosed.

We expect to complete IND-enabling studies in the second half of 2006 and begin a Phase I trial in healthy volunteers for our lead compound, INCB8696, early next year followed by a Phase II trial in MS patients.

New Program

We have a lead compound in preclinical development from a second inflammation program. We expect to complete IND-enabling studies for this compound by year-end and begin Phase I testing early next year.

HIV Opportunity

CCR5 Antagonist

In May, we initiated Phase I testing in healthy volunteers for our oral CCR5 antagonist compound, INCB9471, and expect to initiate a Phase IIa trial in treatment-experienced HIV patients in October of this year. In parallel with the development of INCB9471, we are moving a second CCR5 compound, INCB15050, forward. This compound is expected to complete IND-enabling toxicology studies later this year.

Diabetes Opportunity

11-beta hydroxysteroid dehydrogenase type 1 (11beta-HSD1) Program

We initiated Phase I testing for INCB13739 in June and expect to complete the single- and multiple-dose Phase I trials for this compound in the third quarter. In addition to safety and tolerability, the Phase I program will include an assessment of the ability of INCB13739 to inhibit 11beta-HSD1 activity in adipose tissue. Recently published data suggest that 11beta-HSD1-mediated production of cortisol within metabolically important tissues such as adipose may play a key role in regulating the body's resistance to insulin in people with Type 2 diabetes. We expect to initiate a one-month Phase IIa study in Type 2 diabetic patients either later this year or in January of 2007 which will allow us to evaluate the effect of this compound on glucose production and insulin sensitivity.

Conference Call Information

Incyte will host a conference call on Thursday, July 27, 2006 at 8:30 a.m. ET to discuss the news contained in this release. The domestic dial-in number is 877-692-2592 and the international dial-in number is 973-935-8599. The conference ID number is 7610686.

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-519-4471 and the dial-in number for international callers is 973-341-3080. The replay pin number is 7610686.

The conference call will also be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company with a growing pipeline of novel oral compounds to treat cancer, inflammation, HIV and diabetes.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements with respect to expectations of advancing Incyte's preclinical and clinical compounds, expectations for the timing of the initiation of Phase IIa clinical trials for Incyte's CCR5 antagonist compound INCB9471 and regarding the potential competitiveness of this compound, expectations regarding the timing of completion of IND-enabling studies for Incyte's CCR5 antagonist compound INCB15050, expectations regarding the timing of initiation and completion of IND-enabling studies, Phase I and Phase II clinical trials for the CCR2 antagonist for the treatment of multiple sclerosis, expectations regarding the timing of completion of IND-enabling studies and initiation of Phase I clinical trials for the new inflammation compound in preclinical development, the plans and expectations for our Phase I/II and Phase II trials for Incyte's lead sheddase inhibitor compound, expectations for the timing of filing of an IND for Incyte's new development candidate for cancer, the expected utility and plans and timing for the completion of Phase I and initiation of Phase IIa clinical testing of INCB13739, the positioning of the Company for growth from internal programs, expectations regarding the Company's research and development expenses and interest income, and expectations of the Company's cash use, are all forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the high degree of risk associated with drug development and clinical trials, results of further research and development, the impact of competition and of technological advances and the ability of Incyte to compete against parties with greater financial or other resources, unanticipated delays, unanticipated cash requirements and the ability to raise additional capital, the ability to implement technological improvements, Incyte's ability to enroll a sufficient number of patients for its clinical trials, and other risks detailed from time to time in Incyte's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2006. Incyte disclaims any intent or obligation to update these forward-looking statements.


INCYTE CORPORATION
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)

Three Months Ended Six Months Ended
June 30, June 30,

2006 2005 2006 2005
--------- --------- --------- ---------
Revenues:
Contract revenues $ 6,292 $ - $ 11,821 $ -
License and royalty revenues 563 2,676 1,499 5,591
--------- --------- --------- ---------

Total revenues 6,855 2,676 13,320 5,591
--------- --------- --------- ---------

Costs and expenses:
Research and development 19,724 26,556 44,481 44,320
Selling, general and
administrative 3,421 2,734 7,297 5,534
Other expenses 2,890 446 3,091 789
--------- --------- --------- ---------

Total costs and expenses 26,035 29,736 54,869 50,643
--------- --------- --------- ---------

Loss from operations (19,180) (27,060) (41,549) (45,052)
Interest and other income, net 2,596 5,420 11,482 7,571
Interest expense (3,891) (4,130) (7,750) (8,447)
Gain on repurchase of
convertible subordinated
notes - 421 - 421
Gain (loss) on certain
derivative financial
instruments, net (45) 39 (9) (87)
--------- --------- --------- ---------
Loss from continuing
operations before income
taxes (20,520) (25,310) (37,826) (45,594)
Provision for income taxes - (156) - (156)
--------- --------- --------- ---------
Loss from continuing
operations (20,520) (25,154) (37,826) (45,438)
Income from discontinued
operations - 9 - 162
--------- --------- --------- ---------
Net loss $(20,520) $(25,145) $(37,826) $(45,276)
========= ========= ========= =========

Basic and diluted net loss per
share:
Continuing operations $ (0.24) $ (0.30) $ (0.45) $ (0.54)
Discontinued operations - - - -
--------- --------- --------- ---------
$ (0.24) $ (0.30) $ (0.45) $ (0.54)
========= ========= ========= =========

Shares used in computing basic
and diluted net loss per
share 83,786 83,303 83,706 83,176
========= ========= ========= =========


INCYTE CORPORATION
Condensed Consolidated Balance Sheet Data
(in thousands)

June 30, December 31,
2006 2005
------------ ------------

Cash, cash equivalents, and marketable
securities $ 352,653 $ 344,971
Total assets 375,112 374,108
Convertible subordinated notes 348,673 341,862
Total stockholders' deficit (54,725) (19,397)



Biotech News

Invitrogen Corporation IVGN - U.S. BioDefense Receives $200,000 Commitment from Equity Solutions and BofA Analyst Upgrades Invitrogen

Invitrogen Corporation IVGN - U.S. BioDefense Receives $200,000 Commitment from Equity Solutions and BofA Analyst Upgrades Invitrogen


08/09/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). U.S. BioDefense, Inc. (OTC BB: UBDE) announced recently it has received a $200,000 commitment from Equity Solutions, Inc. for corporate development and identifying merger and acquisition candidates. The funding commitment entails Equity Solutions to assist with shareholder relations, introduction to other funding sources, building a management team and strategic alliances. Genta Incorporated (Nasdaq: GNTA) recently announced financial results for the second quarter 2006. "The Company continues to make solid progress in our Clinical, Regulatory, Manufacturing, and Sales and Marketing activities as we prepare for the potential U.S. launch of Genasense," commented Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer of Genta.

Invitrogen Corp. (Nasdaq:IVGN), an advanced lab research equipment and services company, was upgraded by a Bank of America analyst Tuesday, who cited its cheap valuation as well as potential benefits from its research and development investments. In a client note, analyst Frank Pinkerton upgraded the Carlsbad, Calif.-based company to "Buy" from "Neutral," citing valuation and new market opportunities, specifically in the molecular diagnostic and biodefense markets. Martek Biosciences (Nasdaq:MATK) said Tuesday it will supply nutritional oils for infant formula manufactured by Hain Celestial Group Inc., an organic food company, and two firms are in ongoing talks to use Martek's fatty acids in other food and beverage products. Hain Celestial recently unveiled a new infant formula marketed under the Earth's Best brand, a leading organic baby and toddler food manufacturer.


Biotech News

SeraCare Life Sciences OTC:SRLSQ - SeraCare gets month extension to file Chapter 11 plan

SeraCare Life Sciences OTC:SRLSQ - SeraCare gets month extension to file Chapter 11 plan

Aug. 4 is deadline for shareholder deal also
UNION-TRIBUNE STAFF AND NEWS SERVICES
July 12, 2006

SeraCare Life Sciences has received an extension to Aug. 4 to file a Chapter 11 plan and work out a deal with shareholders trying to end the company's exclusive control over its bankruptcy case.

The Oceanside company said in court papers filed Friday that it has reached an agreement with an ad hoc committee of shareholders to extend by a month the company's exclusive period to file a plan.

The agreement also gives the company through Oct. 4 to win creditors' support for the plan.

The deal comes after the shareholder group asked the U.S. Bankruptcy Court in San Diego to end SeraCare's exclusive control over its Chapter 11 case so that the group could file its own turnaround plan for the company.


Biotech News

Oscient Pharmaceuticals Corporation OSCI - Abbott Gets Oscient Drug Canada License and AstraZeneca Says Has Full Confidence in Toprol XL Patents

Oscient Pharmaceuticals Corporation OSCI - Abbott Gets Oscient Drug Canada License and AstraZeneca Says Has Full Confidence in Toprol XL Patents

08/11/2006 - Pharmaceuticals Instruments industry news provided by Financial News USA (OTC: FNWU). Biotech drug maker Oscient Pharmaceuticals Corp. said Thursday it granted the Canadian unit of Abbott Laboratories Inc.'s (NYSE:ABT) rights to sell its anti-infective product Factive in Canada. Factive is approved in Canada to treat chronic bronchitis caused by bacteria over five days. Abbott Canada will launch the product in the coming months. "With 1,400 employees and a sales force experienced in building leading anti-infective brands, Abbott Canada is well-positioned to launch Factive in Canada," said Steven M. Rauscher, Oscient president and chief executive, in a statement. Biopharmaceutical Company MGI Pharma Inc. (Nasdaq:MOGN) said Thursday the U.S. Food and Drug Administration gave its leukemia drug Dacogen orphan drug status. The classification gives the company government incentives to further develop the drug, including up to seven years of marketing exclusivity. Dacogen has already received such status in the U.S. for Myelodysplastic Syndromes, or bone marrow disorders, and was approved for that use by the FDA May 2.

Drug maker AstraZeneca (NYSE:AZN) said that it continues to have full confidence in the intellectual property rights protecting its heart drug Toprol XL. It made the statement after the U.S. Food & Drug Administration granted approval to Novartis' Sandoz for 25 mg of metoprolol succinate, a generic form of Toprol XL, on August 1. The patent protecting Toprol XL expires in September next year. CytoDyn, Inc. (OTCBB:CYDY) has been invited to present clinical results from Cytolin® at the Treatment Horizons Forum of The AIDS Institute to be held on August 12, 2006 in conjunction with the XVI International AIDS Conference in Toronto. "CytoDyn will show how its targeted immune therapy reduces viral activity while avoiding the emergence of drug-resistant strains of HIV," according to Allen D. Allen, the Company's CEO.


Wednesday, August 09, 2006

Cardinal Health, Inc. CAH - MedivoxRx Technologies Brings Rex-The Talking Prescription Bottle to Las Vegas for Cardinal Health

Cardinal Health, Inc. CAH - MedivoxRx Technologies Brings Rex-The Talking Prescription Bottle to Las Vegas for Cardinal Health - Retail Business Conference


MedivoxRx Technologies Inc., a division of Wizzard Software Corp. (OTCBB:WIZD), has announced they are currently presenting Rex-The Talking Prescription Bottle at the 16th Annual Cardinal Health Retail Business Conference (RBC) 2006 at the MGM Grand in Las Vegas. Located at booth 304, MedivoxRx Technologies is one of the more than 275 suppliers featured during the trade show. At last year's conference, Cardinal hosted more than 1,400 independent and community pharmacies, with 4,000 pharmacists, pharmacy technicians and other pharmacy industry professionals in attendance.

Throughout the week, MedivoxRx is showcasing the Rex Pharmacy System. Using the microphone recording units, prescription label information is recorded to the Rex bottle through microelectronic technology embedded in the base of each bottle. In addition to label information, other important or helpful information may be recorded into the bottle. To playback the recorded information, users simply press a button on the side of the bottle and listen to the message.



Cardinal Health customers can order Rex Bottles (Case of 24 Talking Bottles - CHI # 3675204) and Recorders (Recorder with Microphone - CHI # 3675246) during the show at the MedivoxRx booth.

Also available from MedivoxRx is the Rex Pharmacy Software. Full automation through text-to-speech technology allows pharmacists to automatically record the medication information to the Rex bottle in a natural-sounding computer generated voice using the pharmacy's current software and data. When the pharmacist releases the medication instructions to the standard label printer, the MedivoxRx software captures that text, converts it to speech and records it into the bottle.

"We are very excited to be exhibiting at Cardinal Health RBC," said Gene Franz, General Manager of Solutions and Channels for MedivoxRx. "It's a fantastic opportunity to put Rex in front of so many Cardinal Health (NYSE:CAH) customers and inform them on the benefits of providing their patients with an easy-to-use, cost-effective device that can help manage prescriptions, safeguard health and save lives."

Rex-The Talking Prescription Bottle contributes a solution to the growing medication error problem in the United States. The Journal of the American Medical Association reports medication errors and/or adverse drug events kill an estimated 100,000 persons annually and represent the fourth leading cause of death in the U.S. The first three are heart disease, cancer, and stroke.

Further, Rex is a useful tool for the numerous individuals who take multiple medications. According to an AARP survey, people ages 45 and over take 4 prescription medications per day. Also, a report issued by the National Center for Health Statistics released in 2004 estimates more than 20 percent of all patients age 75 and older were taking five or more prescription drugs. While the average number of prescription drugs a 75 year old takes each day is 5, in many instances older people are using 12 or more prescriptions.

About Wizzard Software:

Founded in 1996, Wizzard Software has become a leader in the speech technology application development market. Wizzard architects solutions to business problems using its expertise in consulting, speech development tools and building speech based applications for the Desktop and Internet. Wizzard has achieved global recognition because of its expertise with voice communication whether it is via PC or telephone. Wizzard's successes have lead to expanding opportunities in both the government and commercial sectors. In April of 2004, Wizzard acquired MedivoxRx Technologies. Established in 2000, MedivoxRx is the originator of "Rex", the talking prescription pill bottle, which "talks" to the patient allowing them to distinguish what type of medication is in the bottle and hear critical information on dosage amounts and refill parameters. Additional information on MedivoxRx can be found at www.rxtalks.com. More information on Wizzard Software can be found on the Investor's Page at www.wizzardsoftware.com.

Legal Notice

Legal Notice Regarding Forward-Looking Statements: "Forward-looking Statements" as defined in the Private Securities litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services, changes in our business strategies and acts of terror against the United States.

Gilead Sciences, Inc. GILD - Gilead Sciences Exercises Option to Acquire Corus Pharma for $365 Million

Gilead Sciences Exercises Option to Acquire Corus Pharma for $365 Million


Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has exercised its option to purchase privately-held Corus Pharma for $365 million. The transaction is expected to close in the third quarter, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and is expected to be dilutive to Gilead's 2006 and 2007 earnings.

On July 19, Gilead notified Corus of its intention to exercise its option to acquire the company. In April 2006, Gilead invested $25 million in Corus, becoming the second largest shareholder in the company and gaining an exclusive option to purchase the remaining shares of the company.

Corus' lead product candidate, aztreonam lysine for inhalation, is an inhaled antibiotic with activity against Gram-negative bacteria including Pseudomonas aeruginosa, which can cause lung infections in patients with cystic fibrosis (CF). Phase III studies to evaluate the product as a potential treatment for CF-related pulmonary infections are currently enrolling. In addition to aztreonam lysine, Corus is exploring an inhalation formulation of two antibiotics for the potential treatment of respiratory infections. This program is currently in preclinical development. The company is also exploring treatments for other respiratory diseases such as chronic cough and asthma.

"Cystic fibrosis represents an important area of unmet medical need and the early exercise of this option underscores the potential therapeutic advancement we believe aztreonam lysine represents for patients," said John F. Milligan, PhD, Executive Vice President and Chief Financial Officer, Gilead Sciences. "We intend to retain Corus' Seattle-based operations, and we look forward to welcoming the Corus employees to Gilead and to working together to advance the development of aztreonam lysine."

"We are excited to partner our efforts with a company that has demonstrated expertise and success in developing and commercializing novel products for infectious diseases, and whose leadership underscores the difference we can make for patients and physicians," said A. Bruce Montgomery, MD, Chief Executive Officer of Corus. "The completion of this transaction will help Corus more rapidly develop aztreonam lysine and will fuel additional progress across our research pipeline."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

About Corus Pharma

Corus Pharma is committed to developing and commercializing specialty products for respiratory and infectious diseases that can help provide improved health and superior quality of life. Corus is a privately-held, venture capital backed company whose investors include Bear Stearns Health Innoventures, Burrill & Company, JPMorgan Partners (now known as Panorama Capital), Novo A/S, Orbimed Advisors and others. More information about Corus Pharma may be found at www.coruspharma.com.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors including the risks to both companies that the acquisition of Corus will not be consummated as the transaction is subject to certain closing conditions. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to our ability to successfully integrate the products and employees of Gilead and Corus and the ability of aztreonam lysine for inhalation to receive regulatory approvals or market acceptance. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2005, Quarterly Report on Form 10-Q for the first quarter of 2006 and subsequent current reports on Form 8-K as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.

Genzyme Corporation GENZ - American Kidney Fund, Genzyme Announce New Medicare Part D Assistance Program for Renagel

Genzyme Corporation GENZ -American Kidney Fund, Genzyme Announce New Medicare Part D Assistance Program for Renagel

Genzyme Corp.
July 31, 2006, The American Kidney Fund and Genzyme Corp. announced today that they have launched a new program to provide Renagel® (sevelamer hydrochloride) free of charge to patients who are enrolled in a Medicare prescription drug plan, but cannot afford their co-payments or co-insurance payments for Renagel.


The Medicare Part D Assistance Program will help those facing high payments in and out of the Medicare coverage gap known as the "doughnut hole." To be eligible, patients must be enrolled in a Medicare Part D prescription drug plan, have no alternative insurance, meet pre-specified income criteria, and have spent a pre-specified percentage of their income on prescription drugs. Patients who qualify will receive Renagel through the end of 2006 at no cost.


"Genzyme is delighted to expand our partnership with the American Kidney Fund to ensure that Renagel is accessible to all patients who need it," said John P. Butler, president and general manager, Genzyme Renal. "High Medicare co-payments can pose a serious obstacle for many patients, and we are committed to helping Medicare patients access Renagel."


The Medicare Part D Assistance Program for Renagel is administered by the American Kidney Fund as part of its continued efforts to improve the care of kidney disease patients. Genzyme’s partnership with AKF dates back to 2001, when the two organizations launched the Renagel Patient Assistance ProgramSM (RPAP), which provides access to Renagel and Hectorol® (doxercalciferol) for those not otherwise able to access these products.


Healthcare providers can contact Genzyme’s Renassist case managers to qualify their Medicare patients for the program by calling 800-847-0069.


About Renagel® (sevelamer hydrochloride)


Renagel controls serum phosphorus in patients with Chronic Kidney Disease on hemodialysis. The National Kidney Foundation’s 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride as a first-line treatment option to reduce phosphorus. Renagel is the only phosphate binder available that does not contain either calcium or a metal. It has an established safety profile, is not systemically absorbed and provides phosphorus control without the concerns of calcium or metal accumulation. Renagel has been used by more than 600,000 people in the United States since it was introduced in 1998.


Renagel® is indicated for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis. Renagel® is contraindicated in patients with hypophosphatemia or bowel obstruction. In a 52 week study, the most common side effects were not dose-related and included vomiting, nausea, diarrhea, and dyspepsia. In drug interaction studies, Renagel® had no effect on the bioavailability of digoxin, warfarin, enalapril, metoprolol or iron. When administering any other oral drug for which alteration in blood levels could have a clinically significant effect, the drug should be administered at least 1 hour before or 3 hours after Renagel®, or the physician should consider monitoring blood levels of the drug.


For more information about Renagel, including complete prescribing information, please visit www.renagel.com.


About Genzyme


One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25th anniversary of Genzyme’s founding. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 8,000 employees in locations spanning the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.


With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.


About the American Kidney Fund


The American Kidney Fund is our nation’s leading voluntary health organization serving people with and at risk for kidney disease through direct financial assistance, comprehensive education, clinical research and community service programs. In 2004, the Fund served more than 55,000 low-income kidney patients, distributing more than 100,000 grants totaling $57 million. For more information, please visit the Fund website: www.kidneyfund.org, or call (800) 638-8299.


Genzyme® and Renagel® are registered trademarks of Genzyme Corporation. Renagel Patient Assistance ProgramSM and Renagel REACH ProgramSM are service marks of Genzyme Corporation. All rights reserved.

Invitrogen Corporation IVGN - U.S. BioDefense Receives $200,000 Commitment from Equity Solutions and BofA Analyst Upgrades Invitrogen

U.S. BioDefense Receives $200,000 Commitment from Equity Solutions and BofA Analyst Upgrades Invitrogen


City of Industry, CA --(www.FinancialNewsUSA.com)-- 08/09/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). U.S. BioDefense, Inc. (OTC BB: UBDE) announced recently it has received a $200,000 commitment from Equity Solutions, Inc. for corporate development and identifying merger and acquisition candidates. The funding commitment entails Equity Solutions to assist with shareholder relations, introduction to other funding sources, building a management team and strategic alliances. Genta Incorporated (Nasdaq: GNTA) recently announced financial results for the second quarter 2006. "The Company continues to make solid progress in our Clinical, Regulatory, Manufacturing, and Sales and Marketing activities as we prepare for the potential U.S. launch of Genasense," commented Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer of Genta.

Invitrogen Corp. (Nasdaq:IVGN), an advanced lab research equipment and services company, was upgraded by a Bank of America analyst Tuesday, who cited its cheap valuation as well as potential benefits from its research and development investments. In a client note, analyst Frank Pinkerton upgraded the Carlsbad, Calif.-based company to "Buy" from "Neutral," citing valuation and new market opportunities, specifically in the molecular diagnostic and biodefense markets. Martek Biosciences (Nasdaq:MATK) said Tuesday it will supply nutritional oils for infant formula manufactured by Hain Celestial Group Inc., an organic food company, and two firms are in ongoing talks to use Martek's fatty acids in other food and beverage products. Hain Celestial recently unveiled a new infant formula marketed under the Earth's Best brand, a leading organic baby and toddler food manufacturer.

Amgen, Inc. AMGN - Invitrogen 2Q Profit Rises and Amgen Wins Patents Appeal and Amorfix and Biogen to Collaborate on ALS

Invitrogen 2Q Profit Rises and Amgen Wins Patents Appeal and Amorfix and Biogen to Collaborate on ALS


City of Industry, CA --(www.FinancialNewsUSA.com)-- 08/04/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Advanced lab research equipment and services company Invitrogen Corp. (Nasdaq:IVGN) said Thursday its second-quarter profit jumped 32 percent as it lowered expenses and posted a gain from the sale of its German manufacturing business. The company earned $19.7 million, or 36 cents per share, compared with $14.9 million, or 27 cents per share, a year ago. Pro forma results, which exclude charges and gains from acquisitions and stock option expensing, were 90 cents per share. Amgen Inc. announced Thursday that the Court of Appeals for the Federal Court affirmed a previous decision that Amgen's (Nasdaq:AMGN) erythropoietin (EPO) patent estate was infringed by Transkaryotic Therapies Inc. and Aventis Pharmaceuticals. The appeal reviewed the District Court's findings on the infringement and validity of two patents with claims to the production of erythropoietin; the infringement of one patent under the doctrine of equivelents; and the validity of one product patent.

Biotech Company Amorfix Life Sciences Ltd. said Thursday it struck a research and investment deal with U.S.-based Biogen Idec. (Nasdaq:BIIB) The Toronto company said the deal with Biogen of Cambridge, Mass., includes an option to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize therapeutic treatments for Amyotrophic Lateral Sclerosis, a neurodegenerative condition also known as Lou Gehrig's Disease. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.

Genentech, Inc. DNA - Genentech/Novartis Ophthalmics' Lucentis will Dominate the Market

Genentech/Novartis Ophthalmics' Lucentis will Dominate the Market to Treat Wet Age-Related Macular Degeneration


Increase in the Aging Population and Earlier Awareness Will Help Triple
Drug Treatment Rates, According to a New Report from Decision Resources

Decision Resources, Inc., one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that Genentech/Novartis Ophthalmics' Lucentis
(ranibizumab), a vascular endothelial growth factor (VEGF) inhibitor, will
dominate the market and will become the new standard of care in the
treatment of wet age-related macular degeneration (AMD) by 2015.
The new Pharmacor report entitled Age-Related Macular Degeneration
finds that Lucentis will dominate the wet AMD market either as a
monotherapy or in combination with the current standard of care,
QLT/Novartis Ophthalmics' Visudyne (verteporfin/photodynamic therapy).
Lucentis will command a 52% share of the total AMD market in 2010 and a 62%
share in 2015 in the United States, Japan, France, Germany, Italy, Spain,
and the United Kingdom. The report also finds that an increasing aging
population and earlier awareness of the disease will drive a threefold
increase in the drug-treated population from 2005 to 2015.
"Additionally, more aggressive education, awareness, and screening
could significantly increase the number of patients receiving drug
treatment beyond this estimate," said Regina Cebula, analyst at Decision
Resources, Inc. "We forecast dramatic 23% annual growth in the AMD drug
treatment market from 2005 through 2010 as a result of more widespread use
of premium-priced emerging therapies, including Lucentis, as well as an
increase in the number of patients being diagnosed and treated. Thereafter,
annual market growth will level off to 8% through 2015."
About Age-Related Macular Degeneration
Age-related macular degeneration, an under-treated vision-threatening
disease affecting people over 50 years of age, will directly impact a
significant segment of the increasing aging population. Treatment of the
disease represents considerable commercial potential for developers of
innovative drug therapies. In 2005, the total prevalent population exceeded
3.8 million cases in the world's major pharmaceutical markets.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master
their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
Protests Against $100 Million Covance Lab in Arizona Illustrate Challenges of Medical Research, an Industrial Info News Alert
SUGAR LAND, Texas--(BUSINESS WIRE)--Aug. 9, 2006--Written by Annette Kreuger, VP Pharma-Biotech for Industrial Info Resources (Sugar Land, Texas). The temperature is rising in Maricopa County. Drug development firm Covance (Madison, Wisconsin) touched off a firestorm of emotion with its 2005 purchase of a 38-acre site in Chandler, Arizona. With plans to eventually build out a nearly 600,000-square-foot medical research and animal-testing campus and employ up to 1,200 people, the company had hoped to be greeted with open arms. Instead, they might be semi-seriously considering the need to bear arms against the voracious fight being waged against the construction by an assortment of very vocal animal rights groups scattered across the globe.


For details, view the entire article by subscribing to Industrialinfo.com's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=94615, or browse other breaking industrial news stories at www.industrialinfo.com.

Industrial Info Resources (IIR) is a Marketing Information Service company that has been doing business for over 23 years. IIR is respected as the leader in providing comprehensive market intelligence pertaining to the industrial processing, heavy manufacturing, and energy-related industries throughout the world. For more information send inquiries to pharmabiogroup@industrialinfo.com or visit us at www.industrialinfo.com.

Tuesday, August 01, 2006

Biotech news - TGen/SARRC Research Receives $7.1 Million Boost in State Appropri

Biotech news - TGen/SARRC Research Receives $7.1 Million Boost in
State Appropriations Funding for Autism Research

Represents First Step Toward Securing Funding for a Proposed $50
Million Autism Research Initiative

07-24-2006

Phoenix, AZ, (July 24, 2006) - The Arizona Legislature recently
appropriated $7.1 million to fund autism research at the
Translational Genomics Research Institute (TGen) – part of a joint
research collaboration between TGen and the Southwest Autism
Research & Resource Center (SARRC). The money will help fund
research aimed at producing an early diagnostic test to identify
children at-risk for autism and, moreover, what type of autism an at-
risk child might eventually develop.
The state-appropriated funds are also a launching point for securing
future funding for a TGen-proposed $50 million Arizona Autism
Research Initiative designed to not only improve early detection and
subclassification, but also provide new medicines for autism based
on a firm understanding of who will get it, what form an affected
individual has, and what causes it.

Autism spectrum disorders (ASDs) affect approximately one out of
every 166 children—a statistic that rested at two out of every
10,000 in the early 1990s. ASDs generally appear within the first
three years of life, impairing a child's intuitive thought, as well
as their language and social development facilities. Most
individuals diagnosed with an ASD require lifelong supervision and
care; the most severely affected are unable to speak.

The autism appropriation bill (SB1355) underwent a lengthy
legislative review process in both the Arizona House and Senate. The
bill was evaluated and voted on numerous times by each committee of
jurisdiction including the Health, Appropriations and Rules
committees. Each time the bill received near unanimous support.

"Arizona has decided to focus on this area as a way to make the
biggest impact against the disorder in the shortest amount of time,
based upon our area of competence. Not only is this a unique
opportunity that will benefit those locally and statewide, but
nationally as well," said Dr. Jeffrey Trent, TGen president and
scientific director.

"TGen will address early diagnostic testing with laser-like focus
with these funds," said Dr. Dietrich Stephan, director of
Neurogenomics at TGen and head of the autism research
program. "Earlier diagnosis allows early interventions, which we
know will improve the outcomes of patients with this devastating
disorder. Our larger initiative, for which we are still seeking
funds, will allow development of new, highly effective medicines."

According to lead sponsor of SB1355, Senator Carolyn Allen, Chairman
of the Arizona State Senate Health Committee, "The statistics are
staggering. As many as 1.5 million Americans are currently living
with some form of autism and based on the current growth rate, by
the next decade, the incidence of autism could exceed 4 million
people. Arizona has the opportunity to potentially develop new
treatment options that will benefit patients with autism and their
families."

Arizona State Representative Doug Quelland, Chairman of the House
Health Committee, also championed the bill.

"The Arizona legislature believed that the growing autism epidemic
was so important that both Houses came together to approve the
autism funding bill," said Quelland. "Because it is important to
diagnose autism early, we need to act now in order to quickly find
the answers we need for this growing epidemic."

Leaders from TGen and SARRC, as well as family members whose lives
are personally affected by autism, presented testimony at each
Health and Appropriations committee hearing. Members of the full
Senate and House favorably approved SB1355, which was signed by
Governor Janet Napolitano on June 21, 2006. Governor Napolitano is
only the third governor to sign into law a bill that supports autism
research (other states include California and New Jersey).

"Our Governor and legislative leaders have sent a message to
Arizonans and the rest of the country that our state is taking a
lead in the fight against autism," said Denise D. Resnik, SARRC co-
founder, board chairman and mother of a 15-year-old son with
autism. "Our goal with this funding is to maximize the return on
investment to the children and families in Arizona whose daily lives
are impacted by autism and also to maximize the state's investment
by leveraging national resources, bringing new opportunities to
Arizona and advancing scientific discoveries." # # #

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit
501(c)(3) organization focused on developing earlier diagnostics and
smarter treatments. Translational genomics research is a relatively
new field employing innovative advances arising from the Human
Genome Project and applying them to the development of diagnostics,
prognostics and therapies for cancer, neurological disorders,
diabetes and other complex diseases. TGen's research is based on
personalized medicine. The institute plans to accomplish its goals
through robust and disease-focused research.

About SARRC
Founded in 1997, the Southwest Autism Research & Resource Center
(SARRC) is a nonprofit, community-based organization dedicated to
autism research, education and resources for children and young
adults with autism spectrum disorders (ASDs) and their families.
SARRC undertakes self-directed and collaborative research projects,
serves as a satellite site for national and international projects,
and provides up-to-date information, training and assistance to
families and professionals about ASDs. For more information about
SARRC, call (602) 340-8717 or visit www.autismcenter.org.

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/